A respiratory-vocal pathway in the brainstem of the pigeon

J. Wild,J. Arends

DOI: https://doi.org/10.1016/0006-8993(87)91237-6

IF: 3.61

1987-03-24

Brain Research

Abstract:

What problem does this paper attempt to address?

FLT3 and NPM1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Normal Cytogenetics

Lei Wang,Wei-lai Xu,Hai-tao Meng,Wen-bin Qian,Wen-yuan Mai,Hong-yan Tong,Li-ping Mao,Yin Tong,Jie-jing Qian,Yin-jun Lou,Zhi-mei Chen,Yun-gui Wang,Jie Jin

DOI: https://doi.org/10.1631/jzus.b1000052

2010-01-01

Journal of Zhejiang University SCIENCE B

Abstract:Mutations of fms-like tyrosine kinase 3 (FLT3) and nucleophosmin (NPM1) exon 12 genes are the most common abnormalities in adult acute myeloid leukemia (AML) with normal cytogenetics. To assess the prognostic impact of the two gene mutations in Chinese AML patients, we used multiplex polymerase chain reaction (PCR) and capillary electrophoresis to screen 76 AML patients with normal cytogenetics for mutations in FLT3 internal tandem duplication (FLT3/ITD) and exon 12 of the NPM1 gene. FLT3/ITD mutation was detected in 15 (19.7%) of 76 subjects, and NPM1 mutation in 20 (26.3%) subjects. Seven (9.2%) cases were positive for both FLT3/ITD and NPM1 mutations. Significantly more FLT3/ITD aberration was detected in subjects with French-American-British (FAB) M1 (42.8%). NPM1 mutation was frequently detected in subjects with M5 (47.1%) and infrequently in subjects with M2 (11.1%). FLT3 and NPM1 mutations were significantly associated with a higher white blood cell count in peripheral blood and a lower CD34 antigen expression, but not age, sex, or platelet count. Statistical analysis revealed that the FLT3/ITDpositive group had a lower complete remission (CR) rate (53.3% vs. 83.6%). Survival analysis showed that the FLT3/ITD-positive/NPM1 mutation-negative group had worse overall survival (OS) and relapse-free survival (RFS). The FLT3/ITD-positive/NPM1 mutation-positive group showed a trend towards favorable survival compared with the FLT3/ITD-positive/NPM1 mutation-negative group (P=0.069). Our results indicate that the FLT3/ITD mutation might be a prognostic factor for an unfavorable outcome in Chinese AML subjects with normal cytogenetics, while NPM1 mutation may be a favorable prognostic factor for OS and RFS in the presence of FLT3/ITD.
Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

Yang Shen,Yong-Mei Zhu,Xing Fan,Jing-Yi Shi,Qin-Rong Wang,Xiao-Jing Yan,Zhao-Hui Gu,Yan-Yan Wang,Bing Chen,Chun-Lei Jiang,Han Yan,Fei-Fei Chen,Hai-Min Chen,Zhu Chen,Jie Jin,Sai-Juan Chen

DOI: https://doi.org/10.1182/blood-2011-03-343988

IF: 20.3

2011-01-01

Blood

Abstract:To evaluate the prognostic value of genetic mutations for acute myeloid leukemia (AML) patients, we examined the gene status for both fusion products such as AML1 (CBF alpha)-ETO, CBF beta-MYH11, PML-RAR alpha, and MLL rearrangement as a result of chromosomal translocations and mutations in genes including FLT3, C-KIT, N-RAS, NPM1, CEBPA, WT1, ASXL1, DNMT3A, MLL, IDH1, IDH2, and TET2 in 1185 AML patients. Clinical analysis was mainly carried out among 605 cases without recognizable karyotype abnormalities except for 11q23. Of these 605 patients, 452 (74.7%) were found to have at least 1 mutation, and the relationship of gene mutations with clinical outcome was investigated. We revealed a correlation pattern among NPM1, DNMT3A, FLT3, IDH1, IDH2, CEBPA, and TET2 mutations. Multivariate analysis identified DNMT3A and MLL mutations as independent factors predicting inferior overall survival (OS) and event-free survival (EFS), whereas biallelic CEBPA mutations or NPM1 mutations without DNMT3A mutations conferred a better OS and EFS in both the whole group and among younger patients < 60 years of age. The use of molecular markers allowed us to subdivide the series of 605 patients into distinct prognostic groups with potential clinical relevance. (Blood. 2011;118(20):5593-5603)
FLT3-ITD As a Prognostic Factor for Chinese Patients with Acute Myeloid Leukemia

Jie Sun,Jingsong He,Guoqing Wei,Weiyan Zheng,Jimin Shi,Yi Luo,He Huang

DOI: https://doi.org/10.1182/blood.v128.22.5256.5256

IF: 20.3

2016-01-01

Blood

Abstract:Internal tandem duplication of the FLT3 gene (FLT3-ITD) is one of most common genetic mutations found in patients with acute myeloid leukemia (AML). Although FLT3-ITD has been widely studied and used as an important prognostic indicator of AML in the western world, its association with disease features and prognosis in Chinese AML patients to date has rarely been investigated.In this study, 177 Chinese patients with AML were enrolled including a FLT3-ITD mutation positive group ( n = 83) and a FLT3-ITD mutation negative group ( n = 94).In FLT3-ITD-positive AML patients, the number of patients whose peripheral blood leucocyte count (≥ 100 × 10 9 /L) before treatment was significantly higher than in FLT3-ITD negative patients (32.1% vs 7.6%), but comparing to FLT3-ITD mutation negative patients, 1 year and 2 year event free survival rates (EFSR) of FLT3-ITD-positive AML patients was lower ((37.0% vs 56.0%) and (14.8% vs 38.4%)), and also their 1 year and 2 year OS rates were significantly lower ( (50% vs 100%) and (18.0% vs 36.5%)). However, it was found that the rate of induced remissions in FLT3-ITD-positive AML patients was much lower than in negative patients (39.4% vs 56.0%). The median survival time of the FLT3-ITD+/NPM1- group ( n = 39) was superior to the FLT3-ITD+/NPM1+ group ( n = 27) (16.1 months vs 5.8 months). Lastly, after comparing chemotherapy regimes, we found that the allogeneic hematopoietic stem cell transplantation treatment method significantly improved the survival rate of FLT-ITD positive AML patients (not reached vs 14.5 months). Therefore, for FLT3-ITD-positive Chinese patients with AML, the relative rate of complication with leucocyte was increased; both the event free and overall survival rates were lower, these characteristics are the same as the FLT3-ITD-positive patients in western countries. The lower induced remission rate and shorter survival time suggested FLT3-ITD+/NPM1+ mutation is inferior to FLT3-ITD+/NPM1- mutation, which is not consistant with most reports. In addition, allogeneic hematopoietic stem cell transplantation was clearly an effective treatment for patients with FLT-ITD positive AML in China. Disclosures No relevant conflicts of interest to declare.
Multidimensional Study on the Prognostic Factors of Acute Myeloid Leukemia Patients with FLT3-ITDmutations Based on the Next-Generation Sequencing Platform

Yi Zhang,Bide Zhao,Yungui Wang,Dongmei Wang,Hanzhang Pan,Chengcheng Wang,Feng Lou,Shanbo Cao,Jie Jin

DOI: https://doi.org/10.1182/blood-2018-99-116178

IF: 20.3

2018-01-01

Blood

Abstract:Purpose: This research aimed to investigate the features and effects of FLT3-ITD mutations in Chinese acute myeloid leukemia (AML) population, and to explore whether ITD variant allele frequency (VAF), number of mutations, insertionposition and length will have influence on the patients' overall survival (OS) and relapse-free survival (RFS).
Retrospective Analysis of 59 Cases Flt3-Itd Mutation Positive Acute Myeloid Leukemia

Jie Sun,Juan Hu,Shuangwei Ying,Zhen Cai,Jingsong He,Weiyan Zheng,Yi Luo,Guoqing Wei,Jie Zhang,Xiujin Ye,Wanzhuo Xie,He Huang

DOI: https://doi.org/10.1182/blood.v124.21.5273.5273

IF: 20.3

2014-01-01

Blood

Abstract:Objective: Between October 2010 to May 2014, 59 patients who diagnosed as FLT3-ITD positive aAML were analyzed. All the patients were signed informed consents to agree to provide their clinical information to this study. Informed consents were approved by Ethics Committee. Peripheral white cell count at diagnose; complete remission (CR) rate; the percentage of progressing to refractory leukemia and the response to allogenic stem cell transplantation (allo-SCT) were analyzed. Better therapeutic strategy was explored.
The Clinical Impact of IKZF1 Mutation in Acute Myeloid Leukemia

Xiang Zhang,Aijie Huang,Lixia Liu,Jiayue Qin,Chengcheng Wang,Min Yang,Yinjun Lou,Lei Wang,Xiong Ni,Xiaoxia Hu,Gusheng Tang,Mengmeng Zhang,Shanbo Cao,Liping Mao,Jiejin Qian,Weilai Xu,Juying Wei,Gaixiang Xu,Haitao Meng,Wenyuan Mai,Chunmei Yang,Honghu Zhu,Hongyan Tong,Jianmin Yang,Wenjuan Yu,Jianmin Wang,Jie Jin

DOI: https://doi.org/10.1186/s40164-023-00398-y

2023-01-01

Abstract:Genetic heterogeneity poses a great challenge to the understanding and management of acute myeloid leukemia (AML). Knowledge of the IKZF1 mutation in AML specifically is extremely limited. In a previous work, we described the distribution pattern of IKZF1 mutation in AML, but its clinical impact has remained undefined due to the limited number of cases. Herein, we attempt to answer this question in one relatively large cohort covering 522 newly diagnosed AML patients. A total of 26 IKZF1 mutations were found in 20 AML patients (20/522, 3.83%). This condition has a young median age of onset of morbidity (P = 0.032). The baseline characteristics of IKZF1-mutated and wild-type patients were comparable. IKZF1 mutation showed significant co-occurrences with CEBPA (P < 0.001), SF3B1 (P < 0.001), and CSF3R (P = 0.005) mutations, and it was mutually exclusive with NPM1 mutation (P = 0.033). Although IKZF1-mutated AML was more preferably classified into the intermediate-risk group (P = 0.004), it showed one inferior complete remission rate (P = 0.032). AML with high burden of IKZF1 mutation (variant allele frequency > 0.20) showed relatively short overall survival period (P = 0.012), and it was an independent factor for the increased risk of death (hazard ratio, 6.101; 95% CI 2.278-16.335; P = 0.0003). In subgroup analysis, our results showed that IKZF1 mutation conferred poor therapeutic response and prognosis for SF3B1-mutated AML (P = 0.0017). We believe this work improves our knowledge of IKZF1 mutation.
The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China

Haimei Gou,Juan Zhou,Yuanxin Ye,Xuejiao Hu,Mengqiao Shang,Jingya Zhang,Zhenzhen Zhao,Wu Peng,Yanhong Zhou,Yi Zhou,Xingbo Song,Xiaojun Lu,Binwu Ying

DOI: https://doi.org/10.1007/s13277-015-4601-x

2015-12-16

Tumor Biology

Abstract:While a substantial amount of data on gene mutations related to acute myeloid leukemia (AML) prognosis from western and other populations have been reported, these studies largely describe one or two genes. Additionally, in southwest China, only insufficient data exist regarding FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations have been widely used in clinical settings. Therefore, a comprehensive study about these mutations of clinical importance in the prognosis of AML in western China is necessary. In a cohort of 255 patients with de novo AML, we retrospectively analyzed the prevalence of the six gene mutations, and then we assessed the results in conjunction with clinical characteristics and treatment responses. As for the frequencies of these mutations, the NPM1 mutation occurred most frequently (17.7 %; 42/237), followed by the CEBPA mutation (15.0 %; 19/127) and the FLT3-ITD mutation (10.2 %; 25/244). The frequencies of the FLT3-TKD, DNMT3A, and C-KIT mutations were 3.7 % (9/234), 4.0 % (9/225) and 4.2 % (10/238), respectively. These mutations were closely related to clinical characteristics including FAB classification, gender and age, hemogram, blasts (%), fusion genes, and immunophenotypes. Additionally, a higher complete remission (CR) rate was found in NPM1-mutated patients. The occurrence of these mutations is variable among different countries and regions worldwide, which may provide clues to the etiology of AML. Besides, we identified new clinical characteristics that advance our understanding of these mutations and further clarify the involvement of these mutations in the development of leukemia.
[Clinical Characteristics and Prognosis of Acute Myeloid Leukemia with FLT3-ITD Mutation].

X. Ke,Jing Wang,Ji-Jun Wang,H. Jing,F. Dong,Yan Liu

DOI: https://doi.org/10.7534/j.issn.1009-2137.2018.02.008

2018-04-01

Abstract:OBJECTIVE To investigate the clinical characteristics of acute myeloid leukemia(AML) patients with FLT3-ITD(Fms-like tyrosine kinase3, intenal tandem duplication) mutation and their response to treatment. METHODS Retrospective analysis of 128 newly diagnosed AML (except type M3) patients was performed between January 2014 and July 2017. Patients were divided into FLT3-ITD mutated group and non-mutated group. Mutation detection was carried out by using polymerase chain reaction(PCR) and gene sequencing analysis. Standard 3 + 7 or CAG regimen were taken as the first induction chemotherapy, 4 cases received sorafenib, overall survival (OS) was calculated by Kaplan-Meier. RESULTS Ninety-seven patients can be evaluable for clinical data available; 4 patients were FLT3-TKD mutated, which accounted for 4.1%; 19 patients were FLT3-ITD mutated, which accounted for 19.59%(19/97). Median white blood cell count (WBC), percentage of peripheral blasts and LDH value were significantly higher in FLT3-ITD group than those in non-mutated group [64.65(1.07-587.92)×109/L vs 39.68 (0.45-203.81) ×109/L](P<0.01), [69.62(16-99)% vs 36.35(0-92) %](P<0.01 ) and [LDH 526(124-2 729)U/L vs 265(20-1977)U/L](P<0.05), respectively. The frequency of coexisting NPM1 mutation was higher in FLT3-ITD group than that in non-mutated group [36.8(7/19)% vs 6.8 (5/74) %](P<0.01). The CR+PR was lower in FLT3-ITD group than that in non-mutated group [31.6(6/19)% vs 64.9 (48/74)%](P<0.05). OS in FLT3-ITD group was significantly shorter than that in non-mutated group (5 vs 18 months)(P<0.05). There is no significant difference in OS between FLT3-ITD concomitant with and without NPM1 mutation groups(5 vs 5 months)(P>0.05). The median OS was 13 months for the FLT3-ITD patients taking sorafenib. CONCLUSION The FLT3-ITD is a common mutation in AML, FLT3-ITD mutated AML is more likely concomitant with NPM1 mutation with higher number of WBC, percentage of peripheral blasts and LDH value, thus CR is low after the 1st treatment and survival is poor.

Medicine
Mutation Topography and Risk Stratification for De Novo Acute Myeloid Leukaemia with Normal Cytogenetics and No Nucleophosmin 1 (NPM1) Mutation or Fms‐like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3‐ITD)

Ya-Lan Zhou,Li-Xin Wu,Robert Peter Gale,Zi-Long Wang,Jin-Lan Li,Hao Jiang,Qian Jiang,Bin Jiang,Shan-Bo Cao,Feng Lou,Ying Sun,Cheng-Cheng Wang,Yan-Rong Liu,Yu Wang,Ying-Jun Chang,Lan-Ping Xu,Xiao-Hui Zhang,Kai-Yan Liu,Guo-Rui Ruan,Xiao-Jun Huang

DOI: https://doi.org/10.1111/bjh.16526

2020-01-01

British Journal of Haematology

Abstract:About 25% of patients with newly diagnosed acute myeloid leukaemia (AML) have normal cytogenetics and no nucleophosmin 1 (NPM1) mutation or Fms‐like tyrosine kinase 3 internal tandem duplication (FLT3‐ITD). The prognosis and best therapy for these patients is controversial. We evaluated 158 newly diagnosed adults with this genotype who achieved histological complete remission within two cycles of induction therapy and were assigned to two post‐remission strategies with and without an allotransplant. Targeted regional sequencing at diagnosis was performed and data were used to estimate their prognosis, including relapse and survival. In multivariable analyses, having wild‐type or mono‐allelic mutated CCAAT/enhancer‐binding protein alpha (CEBPA) [hazard ratio (HR) 2·39, 95% confidence interval (CI) 1·08–5·30; P = 0·032), mutated NRAS (HR 2·67, 95% CI 1·36–5·25; P = 0·004), mutated colony‐stimulating factor 3 receptor (CSF3R) (HR 2·85, 95% CI 1·12–7·27; P = 0·028) and a positive measurable residual disease (MRD)‐test after the second consolidation cycle (HR 2·88, 95% CI 1·32–6·30; P = 0·008) were independently correlated with higher cumulative incidence of relapse (CIR). These variables were also significantly associated with worse survival (HR 3·02, 95% CI 1·17–7·78, P = 0·022; HR 3·62, 95% CI 1·51–8·68, P = 0·004; HR 3·14, 95% CI 1·06–9·31, P = 0·039; HR 4·03, 95% CI 1·64–9·89, P = 0·002; respectively). Patients with ≥1 of these adverse‐risk variables benefitted from a transplant, whereas the others did not. In conclusion, we identified variables associated with CIR and survival in patients with AML and normal cytogenetics without a NPM1 mutation or FLT3‐ITD.
[Clinical characteristics and prognosis of 34 cases of acute myeloid leukemia with FLT3 internal tandem duplication and MLL gene rearrangement].

J R Zhou,X Zhang,Y L Zhao,J F Yang,J P Zhang,X Y Cao,Y Lu,D Y Liu,F Y Lyu,J Ouyang,P H Lu

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2018.09.010

2018-01-01

Abstract:Objective: To analyze the clinical characteristics and prognosis of 34 cases of acute myeloid leukemia (AML) with FLT3 internal tandem duplication (FLT3-ITD) and MLL gene rearrangement. Methods: The clinical data of 34 AML patients with FLT3-ITD and MLL gene rearrangement was compared and analyzed for the therapeutic efficacy, prognostic factors when treated with chemotherapy, chemotherapy combined with targeted therapy or allogenic hematopoietic stem cell transplantation (allo-HSCT). Results: Of the thirty-four cases with median age 41 (4-71) years old, 63.6% presented with white blood cells (WBC) greater than 30×10(9)/L, 39.4% greater than 50 × 10(9)/L respectively on admission. M(5) (35.3%) made up the highest proportion. The cytogenetic abnormality reached 61.8%, of which the complex cytogenetic abnormality accounted for 11.8%. Eleven patients (32.35%) had both FLT3-ITD and MLL gene abnormalities. In addition to FLT3 and MLL abnormalities, 23 patients (67.6%) had one or more other gene abnormalities (multiple gene abnormalities). Of the 34 cases, 29.4% patients went into complete remission (CR) after two courses of chemotherapy. 20.6% (7 patients) went into CR after 3 or more courses of chemotherapy. The rate of early relapse in the CR group was 52.9%. Patients with WBC>50×10(9)/L or multiple gene abnormalities had a lower remission rate (7.7%, 5.4%) after two courses of chemotherapy. CR rate for the patients with more than three gene abnormalities was 0. The total 2-year overall survival (OS) in the 34 patients was 28.8% (95% CI 13.5%-46.0%) and the disease-free survival (DFS) was 27.1% (95% CI 12.5%-44.0%). Of the 18 patients treated with chemotherapy alone or chemotherapy combined with targeted therapy, 17 cases died within 2 years and 1 lost follow-up after giving up treatment. For the 16 patients received allo-HSCT, the 3-year OS was 43.4% (95% CI 13.7%-70.4%) and DFS 42.7% (95% CI 13.4%-69.7%). Conclusion: AML patients with FLT3-ITD and MLL gene rearrangement often presented with M(5), accompanied by hyperleukocytosis, cytogenetic or multiple gene abnormalities. Those patients were observed to have low response rate and high early relapse when treated with chemotherapy without allo-HSCT. Patients had multiple gene abnormalities may be an important poor prognostic factor. Allo-HSCT is an effective treatment which could significantly improve the prognosis and survival of AML patients with FLT3-ITD and MLL gene abnormalities.
[Clinical Features and Survival Analysis in Non-M(3) Acute Myeloid Leukemia Patients with ASXL1 Gene Mutation].

W B Jia,J T Liu,X Y Yang,H Y Wu,Y H Wei,C Can,R Q Wang,N He,C Y Gu,D X Ma,C Y Ji

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2022.10.006

2022-01-01

Abstract:Objective: To examine the survival rates and clinical characteristics of people with newly discovered non-M(3) acute myeloid leukemia (AML) who carry the ASXL1 gene mutation. Methods: From January 2016 to April 2021, the clinical information of patients with newly diagnosed non-M(3) AML at Shandong University's Qilu Hospital was retrospectively examined, and their clinical characteristics and survival were compared and analyzed. Gene mutation was detected by next-generation sequencing. Results: ① The study included 256 AML patients who were initially diagnosed and had complete data, including 47 cases of ASXL1 gene mutation-positive (ASXL1(+)) patients and 209 cases of ASXL1 gene mutation-negative (ASXL1(-)) patients. All patients were divided into three groups: elderly (≥60 years old, n=92) , middle-aged (45-59 years old, n=92) , and young (≤44 years old, n=72) . ②WBC, and age were higher in patients with ASXL1 mutations compared to ASXL1(-) patients, while complete response after the first round of treatment (CR(1)) was lower (P<0.05) . In the elderly group, WBC and the proportion of aberrant cells in nuclear cells in ASXL1(+) patients were higher than those in ASXL1(-) patients (P<0.05) . In the young group, the WBC of ASXL1(+) patients was higher than that of ASXL1(-) patients (z=-2.314, P=0.021) . ③IDH2 mutation and ASXL1 mutation was related (P=0.018, r=0.34) . In ASXL1(+) patients, the proportion of peripheral blasts in the high VAF group (VAF>40% ) was higher than that in the low VAF group (VAF<20% ) , and the proportion of aberrant nuclear cells was higher in the duplication and replacement mutation patients than in the deletion mutation patients (P<0.05) . ④The overall survival (OS) and progression-free survival (PFS) of ASXL1(+) patients were shorter than those of ASXL1(-) patients (median, 10 months vs 20 months, 10 months vs 17 months; P<0.05) . The proportion number of aberrant cells in nuclear cells (≥20% ) , complex karyotypes, and TET2 mutation were all independent risk variables that had an impact on the prognosis of ASXL1(+) patients, according to multivariate analysis (P<0.05) . Conclusion: ASXL1-mutated non-M(3) AML patients have higher WBC in peripheral blood, a higher proportion of aberrant cells in nuclear cells, lower CR(1) rate, and shorter OS and PFS. Additionally, a poor prognosis is linked to higher VAF, duplication, and substitution mutations in the ASXL1 gene, as well as the high proportion of aberrant cells in nuclear cells, complex karyotype, and TET2 mutation.
Treatment Patterns and FLT3 Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational Study

Li-Jen Cheng,Benfa Gong,Christopher Young,Prabhuram Krishnan,Ying Wang,Hui Wei,Chunlin Zhou,Shuning Wei,Yan Li,Qiuyun Fang,Jia Zhong,Eric Wu,Yingchang Mi,Jianxiang Wang

DOI: https://doi.org/10.2147/tcrm.s434556

2024-02-13

Therapeutics and Clinical Risk Management

Abstract:Benfa Gong, 1 Li-Jen Cheng, 2 Christopher H Young, 3 Prabhuram Krishnan, 2 Ying Wang, 1 Hui Wei, 1 Chunlin Zhou, 1 Shuning Wei, 1 Yan Li, 1 Qiuyun Fang, 1 Jia Zhong, 4 Eric Q Wu, 5 Yingchang Mi, 1 Jianxiang Wang 1 1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China; 2 Medical Affairs, Astellas Pharma Singapore Pte. Ltd., Singapore; 3 Advanced Informatics & Analytics, Astellas Pharma US Inc., Northbrook, IL, USA; 4 Analysis Group, Inc., Beijing, People's Republic of China; 5 Analysis Group, Inc., Boston, MA, USA Correspondence: Jianxiang Wang, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, People's Republic of China, Tel +86 13821389157, Email Introduction: For acute myeloid leukemia (AML), prognosis is particularly poor in patients harboring FMS-like tyrosine kinase 3 ( FLT3 ) gene mutations, though routine screening for these mutations at diagnosis has been shown to be insufficient. The understanding of the impact of FLT3 mutations on treatment decisions is limited. Methods: In this retrospective, observational study, we investigated the key epidemiological characteristics, treatment patterns and responses among adult patients with newly diagnosed (ND) AML in China, who initiated treatment from January 1, 2015, to December 31, 2019, or progressed to relapsed/refractory (R/R) AML by December 31, 2020. Results: Of the 853 ND AML patients included, 63.4% were screened for FLT3 status, and 20.1% tested positive ( FLT3 MUT ) at initial diagnosis. Of 289 patients who progressed to R/R AML during the study period, 24.9% were screened at the diagnosis of R/R AML, and 19.4% tested positive; 20.5% of screened patients changed FLT3 status at first diagnosis of R/R AML. Initial treatment regimens or treatment responses did not seem to differ in patients with ND AML by FLT3 mutation status. In patients with R/R AML, there was an apparent difference in second-line treatment choices by FLT3 mutation status; however, the number of FLT3 -mutated patients were limited to demonstrate any meaningful distinction. FLT3 -mutated R/R AML was associated with shorter relapse time. Conclusion: Study findings showed that there was a lack of routine testing for FLT3 mutations at first diagnosis of R/R AML, and initial treatment decisions did not differ by FLT3 mutation status. Given the clinical burden of FLT3 MUT , likelihood of FLT3 status changes, and emerging FLT3 inhibitors, further routine FLT3 screening is needed to optimize treatment of R/R AML. Keywords: acute myeloid leukemia, epidemiology, real-world, retrospective study Graphical Acute myeloid leukemia (AML) is the predominant form of leukemia in adults, both globally and in China. 1–3 It is characterized by the rapid proliferation of undifferentiated myeloblasts and a poor prognosis, particularly for older individuals, with most patients relapsing after initial treatment. 4,5 For patients with newly diagnosed (ND) AML, initial treatment comprises induction chemotherapy to reduce leukemic cell numbers to below detectable levels, followed by consolidation therapy to eliminate any remaining leukemic cells and reduce the risk of relapse. 6,7 Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is indicated for use either as first-line therapy in patients achieving remission following chemotherapy, for whom the estimated probability of relapse without allo-HSCT would be >35–40%, or as second-line treatment following relapse after initial chemotherapy. 8 However, relapse after allo-HSCT is relatively common (25–55%), with survival rates after 4 years ranging between 20% and 35%. 9 As an alternative therapeutic pathway, several key genetic mutations have been shown to be closely associated with the pathogenesis of AML and poorer prognoses in AML patients, 10,11 with their inhibition linked to improved clinical outcomes in relapsed/refractory (R/R) AML patients. 12 Recent advances in next-generation sequencing technology have enhanced our understanding of these mutations underlying AML and the genomic heterogeneity between patients, 5 providing an opport -Abstract Truncated-

health care sciences & services
The Clinical and Prognostic Significance of Acute Myeloid Leukemia with FLT3-ITD

D Lin,H Wei,Y Wang,C L Zhou,B C Liu,K Q Liu,B F Gong,S N Wei,G J Zhang,Y T Liu,X Y Gong,S W Qiu,Y C Mi,J X Wang

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2016.12.001

2016-01-01

Abstract:Objective: To investigate the clinical significance and prognosis factors of acute myeloid leukemia (AML) with FLT3 mutation-internal tandem duplication (FLT3-ITD) and provide more evidence for prognosis evaluation in AML with FLT3-ITD. Methods: The clinical characteristics and outcomes of 98 AML with FLT3-ITD were analyzed. Results: In patients with FLT3-ITD positive AML, the median of WBC and peripheral blood blast at initial diagnosis were 58.2 (0.3-461.8) ×109/L and 42.2 (0-397.1) ×109/L, respectively. The complete remission (CR) rate after one course induction therapy was 60.6% in 71 patients with intermediate or adverse risk. The primary refractory rate was 26.8% in 71 patients with intermediate or adverse risk. The lower number of peripheral blood blast was a favorable factor to achieve CR after one course induction therapy (P=0.009). CR after one course (HR=0.395, 95% CI 0.183-0.85, P=0.001) and allo-transplantation in CR1 (HR=0.180, 95% CI 0.043-0.752, P=0.018) favored longer relapse-free survival (RFS). CR after one course (HR=0.251, 95% CI 0.121-0.523, P< 0.001) and lower number of peripheral blood blast (HR=0.219, 95% CI 0.088-0.545, P=0.003) favored longer overall survival (OS) in AML with FLT3-ITD. Conclusion: FLT3-ITD positive AML with lower number of peripheral blood blast has a relative favorable prognosis. CR after one course and allotransplantation in CR1 are important strategy to improve prognosis in AML with FLT3-ITD.
[Clinical Characteristics and Prognostic Relevance of Co-Mutated Genes in Acute Myeloid Leukemia Patients with FLT3 Mutations]

Yang Chen,Yan-Yan Xie,Yu Fang,Ming Hong,Wen-Jie Liu,Xuan Zhou,Wei Zhang,Jin-Ning Shi,Si-Xuan Qian

DOI: https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.04.009

Abstract:Objective: To investigate the clinical characteristics and influence of co-mutated gene on acute myeloid leukemia patients (AML) with FMS-like tyrosine kinase-3 (FLT3) mutations. Methods: A total of 273 FLT3+ AML patients were enrolled, and the co-mutation gene data of the patients were collected to further analyze the prognosis of the patients. FLT3 and other common mutations were quantified by PCR amplification products direct sequencing and second-generation sequencing (NGS). Results: When patients were divided into FLT3- ITD +, FLT3- TKD +, FLT3- ITD ++TKD + and FLT3- ITD -+TKD - group according to the type of FLT3 mutations, it was found that the frequencies of TET2, GATA2, NRAS and ASXL1 mutation were significantly different among the 4 groups (all P < 0.05). When patients were divided into allelic ratio (AR) ≥0.5 and <0.5 group, it was found that the frequencies of FLT3- ITD +, FLT3 -ITD - +TKD -, NPM1, NRAS and C-kit were significantly different between the two groups (all P < 0.05). When patients were divided into normal and abnormal karyotype group, it was found that the frequencies of FLT3- ITD +, FLT3- TKD +, NPM1, GATA2 and C-kit were significantly different between the two groups (all P < 0.05). The median overall survival (OS) of AML patients with FLT3 -TKD + (including FLT3- ITD ++TKD +) was longer than that of patients with FLT3- ITD + alone (P < 0.05). The OS and relapse-free survival (RFS) of AML patients with FLT3++TET2+ were both shorter than those of patients with FLT3++TET2- (both P < 0.05). Conclusion: The mutation frequencies of co-mutated genes are correlated with subtypes of FLT3, karyotype and AR. AML patients with FLT3 -TKD + have longer OS than patients with FLT3- ITD + alone, and patients with co-mutation of TET2 have shorter median OS and RFS.
The Clinical Significance of Fms-Like Tyrosine Kinase3 Expression for Evaluating the Prognosis of Acute Myeloid Leukemia

PANG Li-ping,CHEN Tian-tian,XU Hai-chan,XU Lei,FENG Jia,ZHANG Wen-li,ZHONG Feng-luan,MENG Qing-xiang

DOI: https://doi.org/10.3760/cma.j.issn.1008-6706.2012.10.012

2012-01-01

Abstract:Objective To explore the clinical significance of fms-like tyrosine kinase3(FLT3) expression in evaluation prognosis of acute myeloid leukemia(AML) prognosis.Methods 50 patients with AML were selected.AML patients with normal karyotype were 20 cases,the abnormal karyotype were 30 cases.3ml bone marrow before themotherapy was aspirated respectively,and the FLT3 gene expression in leukemia cells was detected with polyenzyme chain react(PCR).Results The FLT3 expression rate in AML patients with normal karyotype was 5.0％,and was 26.7％ in AML patients with abnormal karyotype,33.3％ in AML patients with refractory-relapse,and 4.5％ in AML patients with continue remission.The FLT3 expression rate was related with high leukemia cells percentage in bone marrow and high blood cells count in peripheral blood,and was not related with Franch America British(FAB) classification.The free-disease survival(FDS) and overall survived(OS) was shorter in FLT3 expression AML patients than that in no FLT3 expression AML patients.There was a statistical significance between the former and the latter( x2 =4.17,P ＜0.05 ).Conclusion FLT3 was a kind of worse factor in AML patients prognosis,and could guide clinical individual treatment in AML.
[FLT3-ITD Mutation in Newly Diagnosed Patients with Acute Promyelocytic Leukemia].

B. Gong,Ying Wang,D. Lin,H. Wei,Wei Li,Chun-lin Zhou,Bing-cheng Liu,Kaiqi Liu,Guangji Zhang,Yuntao Liu,Yan Li,S. Wei,X. Gong,Xing-li Zhao,S. Qiu,R. Gu,Y. Mi,Jian-Xiang Wang

DOI: https://doi.org/10.7534/j.issn.1009-2137.2016.06.001

2016-01-01

Abstract:OBJECTIVE To evaluate the influence of FLT3-ITD mutation on long term survival of newly diagnosed patients with acute promyelocytic leukemia (APL). METHODS Long term survival of 170 newly diagnosed APL patients was retrospective analyzed. Mutation rate of FLT3-ITD was assayed, and its influence on disease-free survival(DFS) or overall survival (OS) was analyzed. RESULTS The mutation rate of FLT3-ITD in newly diagnosed patients with APL was 14.1%. WBC count at diagnosis was higer in FLT3-ITD positive group than that in negative group, and the mutation rate of FLT3-ITD was highest in high risk group. Induction death rate in FLT3-ITD positive and negative group were 12.5% and 2.9%, respectively (P=0.031). Complete remission(CR) rate in 2 groups were 83.3% and 97.1%(P=0.004). The 5-year OS rates in 2 groups were 87.5±6.8% and 90.6±2.6% (P=0.740). The 5-year DFS in 2 groups were 82.8±9.1% and 83.6±3.4%(P=0.928). CONCLUSION FLT3-ITD mutation is related with high peripheral white blood cell count in APL, the APL with FLT3-ITD mutation has higher induction death rate and lower CR rate than those in that without FLT3-ITD mutation, but FLT3-ITD mutation did not affect on long term DFS and OS.
The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm)

Hui Wei,Chunlin Zhou,Bingcheng Liu,Dong Lin,Yan Li,Shuning Wei,Benfa Gong,Guangji Zhang,Kaiqi Liu,Xiaoyuan Gong,Qiuyun Fang,Yuntao Liu,Shaowei Qiu,Runxia Gu,Zhen Song,Jiayuan Chen,Miao Yang,Junping Zhang,Jingjing Jin,Ying Wang,Yingchang Mi,Jianxiang Wang

DOI: https://doi.org/10.1111/bjh.18113

2022-01-01

British Journal of Haematology

Abstract:The prognostic factors to stratify acute myeloid leukaemia (AML) with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm) into different risk groups remains to be determined. In this retrospective study, we evaluated 171 consecutive patients with newly diagnosed AML with CEBPAdm by a Cox proportional hazards regression model. In univariate analyses, colony stimulating factor 3 receptor (CSF3R) and Wilms tumour 1 (WT1) mutations were associated with poor relapse-free survival (RFS). The induction regimens including homoharringtonine (omacetaxine mepesuccinate) or intermediate-dose cytarabine was associated with favourable RFS and overall survival (OS). The induction regimen including both homoharringtonine and intermediate-dose cytarabine was associated with the most favourable RFS (3-year RFS 84.7%) and OS (3-year OS 92.8%) compared to the conventional cytarabine and daunorubicin regimen (3-year RFS 27.7%, hazard ratio [HR] 0.126, 95% confidence interval [CI] 0.051-0.313, Wald p < 0.001; and 3-year OS 56.4%, HR 0.179, 95% CI 0.055-0.586, Wald p = 0.005). In multivariate analyses, the induction regimen including intermediate-dose cytarabine (HR 0.364, 95% CI 0.205-0.646, Wald p < 0.001) and CSF3R mutations (HR 2.667, 95% CI 1.276-5.572, Wald p = 0.009) were independently associated with RFS. Taken together, we found that induction regimen and CSF3R mutations were independent prognostic factors for AML with CEBPAdm.
CSF3R mutated myeloid neoplasms: beyond chronic neutrophilic leukemia

Ahmed Mohamed,Juehua Gao,Yi-Hua Chen,Yasmin Abaza,Jessica Altman,Lawrence Jennings,Erica Vormittag-Nocito,Madina Sukhanova,Xinyan Lu,Qing Chen

DOI: https://doi.org/10.1016/j.humpath.2024.06.008

IF: 3.526

2024-06-15

Human Pathology

Abstract:CSF3R activating mutation is a genetic hallmark of chronic neutrophilic leukemia (CNL), and is also present in a subset of atypical chronic myeloid leukemia (aCML), but infrequent in other myeloid neoplasms. However, the occurrence of CSF3R mutations in various myeloid neoplasms is not well studied. Here we evaluate the spectrum of CSF3R mutations and the clinicopathologic features of CSF3R mutated myeloid neoplasms. We retrospectively identified CSF3R mutations in a variety of myeloid neoplasms: two CNL, three atypical chronic myeloid leukemia (aCML), nine acute myeloid leukemia (AML), one chronic myelomonocytic leukemia, and one myeloproliferative neoplasm. The prototypic T618I mutation was found in 50% of cases: CNL (2/2), aCML (2/3) and AML (4/9). We observed a new recurrent CSF3R mutation Q776* in 25% of cases, and a potential-germline mutation in a 20-year-old patient. Co-occurring mutations were often in epigenetic modifier and spliceosome. IDH/RUNX1 and tumor suppressor mutations were frequent in AML but absent in CNL/aCML. All CNL/aCML patients succumbed within 2-years of diagnosis. We demonstrate that CSF3R mutations are not restricted to CNL. CNL and aCML show similar clinicopathologic and molecular features, suggesting that CNL may be best classified as myelodysplastic/myeloproliferative neoplasm rather than myeloproliferative neoplasm.

pathology
Clinical Features and Prognosis in MLL-AF10 Positive Acute Leukemia

Li'na Wang,Yazhen Qin,Jinsong Jia,Ting Zhao,Jing Wang,Shenmiao Yang,Lei Wen,Jin Lu,Xiaojun Huang

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2015.10.007

2015-01-01

Abstract:OBJECTIVE:To analyze the clinical features and prognosis of acute leukemia patients with the mixed lineage leukemia（MLL）gene rearrangements AF10 positive. METHODS:6 cases with MLL-AF10 positive were analyzed retrospectively, related literatures were reviewed to clarify MLL-AF10 patients'clinical features and prognosis. RESULTS:The median age of 6 cases was 19.5 years old, 5 patients with fever onset, the onset white blood cells of 4 patients were less than 10×10⁹/L. 5 cases were as M₅ and 1 case M₄ according to FAB classification, the level of fusion gene（RQ-PCR）was 0.23%-22.60% when diagnosed, 4 cases had concomitant WT1 gene mutation, flow cytometry disclosed myeloid phenotype. Of 5 evaluated patients achieved the first complete remission after conventional chemotherapy, 2 cases of complex karyotype died, one case died of sepsis in induction, another died from failing of transplantation. 4 out of 5 transplant recipients gained long term survival. CONCLUSION:The MLL-AF10 positive patients were mostly young men, the majority FAB classification was M5 or M4, often onset with fever, low white blood cells and low level of fusion gene, usually associated with WT1 mutation. Conventional chemotherapy produced a high response rate, but easy to relapse, while the complex karyotype had a poor prognosis, allo-HSCT may have the potential to improve the prognosis of MLL-AF10 positive patients.
Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group.

W Wang,X-Q Wang,X-P Xu,G-W Lin

DOI: https://doi.org/10.1177/147323001003800206

2010-01-01

Journal of International Medical Research

Abstract:This study was designed to evaluate the prevalence of fms-like tyrosine kinase-3 (FLT3) gene mutations in the World Health Organization classified subtypes of acute leukaemia (AL), and their prognostic significance in terms of complete remission (CR), leukaemia-free survival (LFS) and overall survival (OS). Of 468 patients, 374 (79.9%) had acute myeloid leukaemia (AML) and 83 (17.7%) had acute lymphoblastic leukaemia (ALL). Among the AML patients, a FLT3 internal tandem duplication (FLT3/ITD) mutation was present in 59 cases (15.8%), whereas a FLT3/D835 mutation was detected in 15 cases (4.0%). Conversely, in the ALL patients, no FLT3/ITD mutations were detected and a FLT3/D835 mutation was found in only two cases (2.4%). The FLT3/ITD mutation was associated with a lower CR rate compared with those with no mutations (52.3% versus 71.1%) and with a shorter median OS (9 versus 18 months) in AML patients. In conclusion, the FLT3/ITD mutation occurred frequently in AML and was associated with a lower CR and shorter median OS. In contrast, FLT3/D835 mutations were not of prognostic value.

A respiratory-vocal pathway in the brainstem of the pigeon

FLT3 and NPM1 Mutations in Chinese Patients with Acute Myeloid Leukemia and Normal Cytogenetics

Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia

FLT3-ITD As a Prognostic Factor for Chinese Patients with Acute Myeloid Leukemia

Multidimensional Study on the Prognostic Factors of Acute Myeloid Leukemia Patients with FLT3-ITDmutations Based on the Next-Generation Sequencing Platform

Retrospective Analysis of 59 Cases Flt3-Itd Mutation Positive Acute Myeloid Leukemia

The Clinical Impact of IKZF1 Mutation in Acute Myeloid Leukemia

The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China

[Clinical Characteristics and Prognosis of Acute Myeloid Leukemia with FLT3-ITD Mutation].

Mutation Topography and Risk Stratification for De Novo Acute Myeloid Leukaemia with Normal Cytogenetics and No Nucleophosmin 1 (NPM1) Mutation or Fms‐like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3‐ITD)

[Clinical characteristics and prognosis of 34 cases of acute myeloid leukemia with FLT3 internal tandem duplication and MLL gene rearrangement].

[Clinical Features and Survival Analysis in Non-M(3) Acute Myeloid Leukemia Patients with ASXL1 Gene Mutation].

Treatment Patterns and FLT3 Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational Study

The Clinical and Prognostic Significance of Acute Myeloid Leukemia with FLT3-ITD

[Clinical Characteristics and Prognostic Relevance of Co-Mutated Genes in Acute Myeloid Leukemia Patients with FLT3 Mutations]

The Clinical Significance of Fms-Like Tyrosine Kinase3 Expression for Evaluating the Prognosis of Acute Myeloid Leukemia

[FLT3-ITD Mutation in Newly Diagnosed Patients with Acute Promyelocytic Leukemia].

The prognostic factors in acute myeloid leukaemia with double-mutated CCAAT/enhancer-binding protein alpha (CEBPAdm)

CSF3R mutated myeloid neoplasms: beyond chronic neutrophilic leukemia

Clinical Features and Prognosis in MLL-AF10 Positive Acute Leukemia

Prevalence and prognostic significance of FLT3 gene mutations in patients with acute leukaemia: analysis of patients from the Shanghai Leukaemia Co-operative Group.